Key Highlights

  • Ocean Biomedical is a biomedical company built around research-driven therapeutic programs in oncology, fibrosis and infectious disease.
  • Verified figures are limited given the company's filing difficulties, and any precise real-time price should be treated cautiously.
  • For a company in this position, the near-term questions are about survival and disclosure rather than pipeline milestones.
  • Delisting drastically reduces Liquidity and institutional access, and sub-penny stocks are vulnerable to extreme Volatility and low transparency.

Ocean Biomedical, Inc (OTC:OCEA) is a cautionary example of how quickly a de-SPAC biotech can unravel. The shares now change hands for a fraction of a cent, and the stock's status has shifted dramatically from its Nasdaq debut.

Whatever the exact daily tick, the far larger story is structural: the company lost its Nasdaq listing and now trades over the counter as a sub-penny security, with the kind of erratic percentage moves that come with almost no underlying price and thin trading.

Company and Latest Development

Ocean Biomedical is a biomedical company built around research-driven therapeutic programs in oncology, fibrosis and infectious disease. Its disclosed science has included work on CHI3L1/YKL-40-targeting cancer immunotherapy, a licensing arrangement tied to the inhibitor candidate OAT-3912, and antibodies targeting the malaria protein PfGARP. The company reached public markets through a special-purpose Acquisition company merger, but it soon ran into serious listing-compliance problems. The most consequential recent development is the conclusion of Nasdaq's review process against the company, which cleared the way for its securities to be removed from the exchange.

What Is Driving Attention Around OCEA?

There is no verified same-day catalyst behind the supplied move, and at a price near one-tenth of a cent, a double-digit percentage change can represent an essentially trivial absolute price shift on light volume. The substantive pressure is well documented. Ocean Biomedical received multiple Nasdaq notices related to late periodic filings and failure to meet continued-listing standards, including market-value requirements. After a Nasdaq Listing and Hearing Review Council decision in mid-2025 that was not subject to further review, the exchange moved to delist the company. Stocks pushed off a major exchange into over-the-counter trading typically see collapsing liquidity and extreme volatility.

Key Numbers and Company Position

Verified figures are limited given the company's filing difficulties, and any precise real-time price should be treated cautiously. Market-data providers list OCEA trading at a sub-penny level with a market Capitalization measured in the hundreds of thousands of dollars, a fraction of its post-SPAC valuation, and its 52-week range spans from well under a cent to several dollars. Those numbers illustrate near-total erosion of Equity value. Because the company has struggled with timely SEC reporting, current audited financial detail is not reliably available, so claims here are kept qualitative.

What Could Come Next?

For a company in this position, the near-term questions are about survival and disclosure rather than pipeline milestones. Investors would watch for any catch-up SEC filings, updates on going-concern status, financing or restructuring, and whether management pursues any strategy to regain compliance or list elsewhere. Any concrete progress on its licensed or in-house programs would be notable, but delivering clinical value requires capital that a Delisted micro-cap may struggle to raise.

Risks to Watch

The risks are severe. Delisting drastically reduces liquidity and institutional access, and sub-penny stocks are vulnerable to extreme volatility and low transparency. Going-concern doubts, delinquent filings and potential Insolvency are material threats, and equity holders could be heavily diluted or wiped out in any restructuring. The absence of current, verified financials compounds the uncertainty, and speculative trading at these levels carries a high risk of total loss.

Ocean Biomedical has moved from a Nasdaq-listed de-SPAC biotech to a delisted, sub-penny over-the-counter stock weighed down by compliance failures and going-concern questions. The day-to-day price swings reflect its distressed micro-float far more than any confirmed catalyst. Investors may be watching for overdue SEC filings, any restructuring or financing news, and clarity on the company's ability to continue operating at all.